Last reviewed · How we verify

Propofol + analgesic drug

University Hospital, Brest · Phase 3 active Small molecule

Propofol is a sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia, while the analgesic component provides pain relief.

Propofol is a sedative-hypnotic agent that acts on the central nervous system to induce and maintain anesthesia, while the analgesic component provides pain relief. Used for General anesthesia, Sedation for short procedures.

At a glance

Generic namePropofol + analgesic drug
SponsorUniversity Hospital, Brest
Drug classSedative-hypnotic
TargetGABA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Propofol works by enhancing the inhibitory neurotransmission mediated by GABA, a major inhibitory neurotransmitter in the brain. The analgesic component may work through various mechanisms, including the inhibition of pain signaling pathways in the spinal cord and brain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: